A Prognostic Gene Expression Signature in the Molecular Classification of Chemotherapy-naïve Urothelial Cancer is Predictive of Clinical Outcomes from Neoadjuvant Chemotherapy: A Phase 2 Trial of Dose-dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin with Bevacizumab in Urothelial Cancer

Title

A Prognostic Gene Expression Signature in the Molecular Classification of Chemotherapy-naïve Urothelial Cancer is Predictive of Clinical Outcomes from Neoadjuvant Chemotherapy: A Phase 2 Trial of Dose-dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin with Bevacizumab in Urothelial Cancer

Authors

Keywords

Urothelial cancer, Gene expression profiling, Dose-dense methotrexate cisplatin, Neoadjuvant, Bevacizumab, Basal, Luminal, p53, Subtype

Journal

EUROPEAN UROLOGY

Volume 69, Issue 5, Pages 855-862

Publisher

Elsevier BV

Online

2015-09-03

DOI

10.1016/j.eururo.2015.08.034